In a move that reverberated through hospitals and pharmacies across the nation, the National Pharmaceutical Pricing Authority (NPPA) announced a sweeping revision of the maximum retail price (MRP) for 543 branded cancer medications. The MRP is the ceiling price that manufacturers and distributors are allowed to charge consumers, and it is a critical lever for controlling drug costs in India.
While the overhaul touched more than half a thousand drugs, the spotlight fell on nine particular medications that received the most dramatic price cuts. These nine drugs were selected for significant reductions that will lower expenses for patients. The NPPA's decision to focus on these specific drugs highlights their importance in cancer treatment.
Below is the list of 543 brands of anti cancer medicines with their revised MRP. Check the existing MRP vs Revised MRP. Credit goes to Ministry of Chemicals and Fertilisers, Karnataka. Hope this is done regularly across India.
Among the nine, Narcole—a branded cancer medication—stood out for its staggering 89.51% reduction in MRP. This substantial cut places Narcole at a more accessible price point for patients. The new pricing structure makes this treatment more affordable for those who need it.
Cancer care is expensive, and the financial strain on patients can be significant.
Cancer care is expensive, and the financial strain on patients can be significant. By lowering the MRP, the NPPA reduces the cost burden on families. The cuts also demonstrate a commitment to making essential medications more affordable for cancer patients across India.
“If we can predict the [protein's] shape, we can design a drug that recognizes the harmful form and leaves the healthy one alone.” A Hopkins-led team backed by up to $52M from @ARPA_H will build an AI model to decode how proteins misfold in Parkinson’s, cancer, and other diseases. https://t.co/8DIhsDzYX9
The price cuts benefit multiple stakeholders in healthcare. The policy reflects ongoing efforts to balance medication costs with patient needs. The NPPA's initiative demonstrates that regulatory intervention can yield substantial savings for patients requiring cancer treatment.
While the immediate relief is significant, the long-term impact of these price reductions remains to be seen. The NPPA's initiative shows that regulatory action can make essential medications more affordable. As India continues to address cancer treatment costs, the agency's latest move offers a positive development for patients seeking affordable care.
The highest reductions were seen in the chemotherapy medicines Thiotepa for which the price goes down from R80,071 to R7,150 for a 100mg vial. This was followed by the breast cancer immunotherapy drug Pertuzumab for which the prices reduced from Rs 94,951 to Rs 30,593 for a 30mg vial https://t.co/b4mhcKGjQy